A prospective study to evaluate the clinical usefulness of radioimmunodetection of melanoma in clinical practice is ongoing at the National Cancer Institute of Milan, Italy. Technical conditions for the application of the method were previously reported. In this trial, 99mTc-labelled F(ab’) 2 fragments of the 225.28S monoclonal antibody were used against a high molecular weight melanoma associated antigen (HMW-MAA).
Retrospective studies on radioimmunodetection of melanoma have already been made by our group and by other Centers in about 300 patients.
This study concerns the evaluation of the regional extension of primary melanoma. 23 patients with 32 suspected lymphatic involvements of melanoma on the trunk and arms underwent immunoscintigraphy. No false positive results were observed; 3 false negatives, one corresponding to a micrometastasis, were noticed. Specificity corresponds to 100% and sensitivity to 78.6%.
BrownJ.P., WoodburyR.G., HartC.E., HellstromI., HellstromK.E.Quantitative analysis of melanoma-associated antigen P97 in normal and neoplastic tissues.Proc Natl Acad Sci USA1981; 78: 539–43.
2.
BrownJ.P., HewicjR.M., HellstromI., HellstromK.E., Doo-littleR.F., DryerW.J.Human melanoma-associated antigen P97 is structurally and functionally related to transferrin.Nature1982; 296: 171–3.
HellstromK.E., HellstromI., BrownJ.P.Monoclonalanti-bodies to melanoma-associated antigens In: WrightG.L., ed Monoclonal antibodies and cancerNew York: Marcel Dekker Inc1984; 31–47.
5.
LarsonS.M., BrownJ.P., WrightP.W., CarrasquilloJ.A., HellstromI., HellstromK.E.Imaging of melanoma with I-131-labelled monoclonal antibodies.J Nucl Med1983; 24: 123–9.
6.
LarsonS.M., CarrasquilloJ.A., KrohnK.A.. Localization of 131I-labelled P97-specific Fab fragments in human melanoma as a basis for radiotherapy.J Clin Invest1983; 72: 2101–14.
7.
RosenblumM.G., MurrayJ.L., HaynieT.P.. Pharmacokinetics of 111In-labelled anti-p97 monoclonal antibody in patients with metastatic malignant melanoma.Cancer Res1985; 45: 2382–6.
8.
FawwazR.A., WangT.S., EstabrookA.. Immuno-reactivity and biodistribution of indium-111-labeled monoclonal antibody to a human high molecular weight-melanoma associated antigen.J Nucl Med1985; 26: 488–92.
9.
MurrayJ.L., RosenblumM.G., SobolR.E.. Radioim-munoimaging in malignant melanoma with 111Inlabeled monoclonal antibody 96.5.Cancer Res1985; 45: 2376–81.
10.
WilsonB.S., ImaiK., NataliP.G., FerroneS.Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies.Int J Cancer1981; 28: 293–300.
11.
NataliP.G., WilsonB.S., ImaiK., BigottiA., FerroneS.Tissue distribution, molecular profile and shedding of a cytoplasmic antigen identified by the monoclonal antibody 465.12S to human melanoma cells.Cancer Res1982; 42: 583–9.
12.
NataliP.G., BigottiA., CavaliereR., NicotraM.R., FerroneS.Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens.J Natl cancer Inst1984; 73: 13–24.
13.
BuraggiG.L., CallegaroL., MarianiG.. Imaging with 131I-labeled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F(ab’)2 fragments.Cancer Res1985; 45: 3378–87.
14.
BuraggiG.L., CallegaroL., TurrinaA.. Immunoscintigraphy with 1231, 99mTc and 111In-labelled F(ab’)2 fragments of monoclonal antibodies to a human high molecular weight-melanoma associated antigen.J Nucl Med All Sci1984; 28: 283–95.
15.
BuraggiG.L., TurrinA., CascinelliN.. Immunoscintigraphy with antimelanoma monoclonal antibodies. In: DonatoL., BrittonK. eds. ImmunoscintigraphyNew York, London: Gordon Breach; 1986 (in press).
16.
BuraggiG.L., TurrinA., CascinelliN.. radioimmunodetection with an antimelanoma monoclonal antibody.Proc of Europ Nucl Med Congress. London, Sept. 3-6, 1985 (in press).
17.
CallegaroL., FerroneS., PlassioG.. Biochemical characterization of monoclonal antibodies and F(ab’)2 fragments against human melanoma associated antigen labelled with different radioactive isotopes.J Nucl Med All Sci1983; 27: 82.
18.
SnyderW.S., FordM.R., WarnerG.G., WatsonS.B.“S” absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlet No. 11, New York: Society of Nuclear Medicine, 1975.
19.
SiccardiA.G., BuraggiG.L., CallegaroL.. Immunonoscin-tigraphy of human melanoma. A Multicenter Study of the Italian National Research Council.Cancer Res (in press).
